PARK CITY, Utah and HERZLIYA, Israel, July 6, 2021 /PRNewswire/ -- BlueWind Medical, Ltd. a leading innovator of neuromodulation medical devices for the treatment for overactive bladder (OAB), ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Eleven Biotherapeutics, Inc. (Nasdaq:EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, ...
Investigator-initiated Phase 2 trial to evaluate TNX-102 SL’s potential to reduce severity of acute stress reaction (ASR) and frequency of acute stress disorder (ASD) Trial is sponsored by the ...
Christian Daily International on MSN
Africa Study Bible released in e-book format
The Africa Study Bible, a study Bible developed with contributions from African scholars and church leaders, has been ...
Changes are needed at Grand Island's Island Oasis water park. Through consulting firm Waters Edge of Kansas, community input sessions were held in June and August, and an online survey had 489 ...
PARK CITY, Utah--(BUSINESS WIRE)--BlueWind Medical, Ltd., a leader in implantable Tibial NeuroModulation (iTNM) and developer of the Revi ® System, a patient-centric solution for urgency urinary ...
The MarketWatch News Department was not involved in the creation of this content. Data from Phase III OASIS-4 study to be presented for the first time at 2025 ASCO Annual Meeting: -- In the Phase III ...
The FDA has approved the first oral glucagon-like peptide-1 (GLP-1) receptor agonist for weight loss and to reduce the risk ...
Wegovy pill, the first oral GLP-1 for weight loss, is FDA-approved for reducing cardiovascular risks in adults. Phase III OASIS 4 trial showed 16.6% mean weight loss with oral semaglutide, ...
Seattle Children's is partnering on the launch of a study called the 'Oto-Acoustic Signals in SIDS' (OASIS) study that will investigate a possible association between Sudden Infant Death Syndrome ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback